Citadel Advisors’s Insmed INSM Stock Holding History

Citadel Advisors’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$62.1M	Sell	379,700 -53,200	-12%	-$8.18M	0.01%	1162
2025 Q4	$75.3M	Buy	432,900 +92,400	+27%	+$16.9M	0.01%	1065
2025 Q3	$49M	Buy	340,500 +244,700	+255%	+$30M	0.01%	1397
2025 Q2	$9.64M	Buy	95,800 +17,200	+22%	+$1.32M	﹤0.01%	3079
2025 Q1	$6M	Sell	78,600 -116,400	-60%	-$8.9M	﹤0.01%	3595
2024 Q4	$13.5M	Buy	195,000 +113,400	+139%	+$8.17M	﹤0.01%	2603
2024 Q3	$5.96M	Sell	81,600 -100,700	-55%	-$7.43M	﹤0.01%	3668
2024 Q2	$12.2M	Buy	182,300 +105,400	+137%	+$4.09M	﹤0.01%	2526
2024 Q1	$2.09M	Buy	76,900 +11,800	+18%	+$330K	﹤0.01%	5433
2023 Q4	$2.02M	Sell	65,100 -11,500	-15%	-$298K	﹤0.01%	5333
2023 Q3	$1.93M	Buy	76,600 +26,000	+51%	+$595K	﹤0.01%	5280
2023 Q2	$1.07M	Sell	50,600 -8,700	-15%	-$165K	﹤0.01%	6319
2023 Q1	$1.01M	Buy	59,300 +19,500	+49%	+$379K	﹤0.01%	6759
2022 Q4	$795K	Buy	39,800 +16,600	+72%	+$321K	﹤0.01%	7268
2022 Q3	$500K	Buy	23,200 +4,500	+24%	+$108K	﹤0.01%	8451
2022 Q2	$369K	Sell	18,700 -5,100	-21%	-$107K	﹤0.01%	9326
2022 Q1	$559K	Sell	23,800 -1,200	-5%	-$27.9K	﹤0.01%	9113
2021 Q4	$681K	Buy	25,000 +14,800	+145%	+$423K	﹤0.01%	8905
2021 Q3	$281K	Sell	10,200 -19,300	-65%	-$506K	﹤0.01%	11190
2021 Q2	$840K	Buy	29,500 +14,300	+94%	+$424K	﹤0.01%	8803
2021 Q1	$518K	Sell	15,200 -700	-4%	-$26.8K	﹤0.01%	9597
2020 Q4	$529K	Sell	15,900 -13,000	-45%	-$475K	﹤0.01%	8047
2020 Q3	$929K	Sell	28,900 -900	-3%	-$25.9K	﹤0.01%	6174
2020 Q2	$821K	Sell	29,800 -3,700	-11%	-$87.7K	﹤0.01%	6196
2020 Q1	$537K	Buy	33,500 +8,200	+32%	+$194K	﹤0.01%	6353
2019 Q4	$604K	Sell	25,300 -3,900	-13%	-$79.3K	﹤0.01%	6500
2019 Q3	$515K	Buy	29,200 +1,700	+6%	+$32.8K	﹤0.01%	6696
2019 Q2	$704K	Sell	27,500 -4,900	-15%	-$136K	﹤0.01%	6274
2019 Q1	$942K	Buy	32,400 +13,300	+70%	+$345K	﹤0.01%	5702
2018 Q4	$251K	Sell	19,100 -21,400	-53%	-$341K	﹤0.01%	7535
2018 Q3	$819K	Buy	40,500 +26,000	+179%	+$587K	﹤0.01%	5877
2018 Q2	$343K	Buy	+14,500	New	+$373K	﹤0.01%	6981
2018 Q1	–	Sell	-8,800	Closed	-$274K	–	8515
2017 Q4	$274K	Sell	8,800 -69,900	-89%	-$2.06M	﹤0.01%	6604
2017 Q3	$2.46M	Buy	78,700 +26,400	+50%	+$503K	﹤0.01%	3171
2017 Q2	$897K	Buy	52,300 +27,100	+108%	+$463K	﹤0.01%	4240
2017 Q1	$441K	Buy	25,200 +7,800	+45%	+$120K	﹤0.01%	5233
2016 Q4	$230K	Buy	17,400 +6,600	+61%	+$90K	﹤0.01%	6098
2016 Q3	$157K	Buy	+10,800	New	+$135K	﹤0.01%	6441
2016 Q2	–	Sell	-13,800	Closed	-$175K	–	7073
2016 Q1	$175K	Buy	13,800 +7,000	+103%	+$92K	﹤0.01%	5735
2015 Q4	$123K	Buy	6,800 +1,200	+21%	+$21.1K	﹤0.01%	6458
2015 Q3	$104K	Sell	5,600 -800	-13%	-$20K	﹤0.01%	6917
2015 Q2	$156K	Sell	6,400 -200	-3%	-$4.54K	﹤0.01%	6621
2015 Q1	$137K	Buy	6,600 +4,000	+154%	+$70.5K	﹤0.01%	6574
2014 Q4	$40K	Sell	2,600 -5,900	-69%	-$83.7K	﹤0.01%	7358
2014 Q3	$111K	Sell	8,500 -4,600	-35%	-$69.4K	﹤0.01%	6307
2014 Q2	$262K	Sell	13,100 -530,200	-98%	-$7.85M	﹤0.01%	5234
2014 Q1	$10.3M	Buy	543,300 +519,700	+2,202%	+$9.88M	0.01%	1239
2013 Q4	$401K	Buy	23,600 +6,800	+40%	+$104K	﹤0.01%	4266
2013 Q3	$262K	Buy	16,800 +3,600	+27%	+$45.7K	﹤0.01%	4501
2013 Q2	$158K	Buy	+13,200	New	+$135K	﹤0.01%	4865

Other funds holding INSM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's INSM Position: Q1 2026 in Review

Citadel Advisors increased its Insmed (INSM) stake by 89% in Q1 2026, buying an estimated $158M and bringing the position to 2,182,571 shares worth $357M. The position accounts for 0.06% of the portfolio, ranked #260.

Citadel Advisors first reported a position in INSM in Q2 2013 and has held it in 46 quarters since. 670 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

Citadel Advisors held 2,182,571 shares of Insmed worth $357M as of Q1 2026.
Citadel Advisors bought 1,025,276 Insmed shares in Q1 2026, an estimated $158M.
Insmed made up 0.06% of Citadel Advisors's portfolio in Q1 2026, its #260 holding.
Citadel Advisors first reported a position in Insmed in Q2 2013 and has held it in 46 quarters since.
670 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.